|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular & Cellular Proteomics 3:73-81, 2004.
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc.
,
,¶
,||



,**
From the
Research Center for Proteome Analysis, Key Laboratory of Proteomics, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, CAS, Shanghai 200031, Peoples Republic of China; ¶ Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, Peoples Republic of China; and || Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, Peoples Republic of China
To better understand the mechanism underlying the hepatocellular carcinoma (HCC) metastasis and to search potential markers for HCC prognosis, differential proteomic analysis on two well-established HCC cell strains with high and low metastatic potentials, MHCC97-H and MHCC97-L, was conducted using two-dimensional gel electrophoresis followed by matrix-assisted laser desorption/time-of-flight mass spectrometry. Cytokeratin 19 (CK19) was identified and found to be overexpressed in MHCC97-H as compared with MHCC97-L. This result was further confirmed by two-dimensional Western blot analysis and immunofluorescence assay. Furthermore, one-dimensional Western blot analysis showed consistently increased CK19 expression in progressively more metastatic cells. Immunohistochemical study on 102 human HCC specimens revealed that more patients in the CK19-positive group had overt intrahepatic metastases (satellite nodules, p < 0.05; vascular tumor emboli, p < 0.001; tumor node metastatis staging, p < 0.001). CK19 fragment CYFRA 21-1 levels measured in sera from nude mice model of human HCC metastasis with radioimmunoassay increased in parallel with tumor progression and rose remarkably when pulmonary metastases occurred. The results demonstrated that overexpression of CK19 in HCC cells is related to metastatic behavior. Serum CK19 level might reflect the pathological progression in some HCC and may be a useful marker for predicting tumor metastasis and a therapeutic target for the treatment of HCC patients with metastases.
S.-J. D., Y. L., and Y.-X. T. contributed equally to this paper** To whom correspondence should be addressed: Qi-Chang Xia, Shanghai Institute of Biochemistry and Cell Biology, Yueyang Road, Shanghai 200031, China. Tel.: 86-21-54920160; Fax: 86-21-54920171; E-mail: xiaqc{at}sibs.ac.cn; Hong-Yang Wang, Eastern Hepatobiliary Surgery Hospital, No. 225, Changhai Road, Shanghai 200438, China. Tel.: 86-21-25070856; Fax: 86-21-65566851; E-mail: hywangk{at}online.sh.cn; or Zhao-You Tang, Liver Cancer Institute & Zhongshan Hospital of Fudan University, 136 Yixueyuan Road, Shanghai 200032, China. Tel.: 86-21-64037181; Fax: 86-21-64037181; E-mail: zytang{at}scrap.stc.sh.cn
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
X.-R. Yang, Y. Xu, G.-M. Shi, J. Fan, J. Zhou, Y. Ji, H.-C. Sun, S.-J. Qiu, B. Yu, Q. Gao, et al. Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection Clin. Cancer Res., June 15, 2008; 14(12): 3850 - 3859. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamashita, M. Forgues, W. Wang, J. W. Kim, Q. Ye, H. Jia, A. Budhu, K. A. Zanetti, Y. Chen, L.-X. Qin, et al. EpCAM and {alpha}-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma Cancer Res., March 1, 2008; 68(5): 1451 - 1461. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Z. Pang, L.-X. Qin, N. Ren, Z.-Y. Hei, Q.-H. Ye, W.-D. Jia, B.-S. Sun, G.-L. Lin, D.-Y. Liu, Y.-K. Liu, et al. Loss of Heterozygosity at D8S298 Is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma Clin. Cancer Res., December 15, 2007; 13(24): 7363 - 7369. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamashita, A. Budhu, M. Forgues, and X. W. Wang Activation of Hepatic Stem Cell Marker EpCAM by Wnt {beta}-Catenin Signaling in Hepatocellular Carcinoma Cancer Res., November 15, 2007; 67(22): 10831 - 10839. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Sun, B. Xing, Y. Sun, X. Du, M. Lu, C. Hao, Z. Lu, W. Mi, S. Wu, H. Wei, et al. Proteome Analysis of Hepatocellular Carcinoma by Two-dimensional Difference Gel Electrophoresis: Novel Protein Markers in Hepatocellular Carcinoma Tissues Mol. Cell. Proteomics, October 1, 2007; 6(10): 1798 - 1808. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. O. Alsaad, S. Serra, A. Perren, E. Hsieh, and R. Chetty CK19 and CD99 Immunoexpression Profile in Goblet Cell (Mucin-Producing Neuroendocrine Tumors) and Classical Carcinoids of the Vermiform Appendix International Journal of Surgical Pathology, July 1, 2007; 15(3): 252 - 257. [Abstract] [PDF] |
||||
![]() |
C. Li, Y. Hong, Y.-X. Tan, H. Zhou, J.-H. Ai, S.-J. Li, L. Zhang, Q.-C. Xia, J.-R. Wu, H.-Y. Wang, et al. Accurate Qualitative and Quantitative Proteomic Analysis of Clinical Hepatocellular Carcinoma Using Laser Capture Microdissection Coupled with Isotope-coded Affinity Tag and Two-dimensional Liquid Chromatography Mass Spectrometry Mol. Cell. Proteomics, April 1, 2004; 3(4): 399 - 409. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Journal of Lipid Research | ASBMB Today |